**Table 1.** Baseline characteristics of adults commenced on ART in the correctional facility on-site ART programme.

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Baseline characteristics a** | | **Total (n=404)b** | **ART-experienced** | **ART-naive** | **p-value** |
|  |  |  | N=105c | N=299d |  |
| **Gender** | Male | 369 (91.3) | 88 (83.8) | 281 (94.0) | 0.004 |
| **Age** (years) | Median (IQR) | 33 (28-38) | 36 (32-42) | 32 (28-36) | <0.001 |
| **Previous TB (all forms)** | Yes | 42 (10.4) | 13 (12.4) | 29 (9.7) | 0.46 |
| **AIDS defining illnesse** | OHL | 25 (6.2) | 3 (2.9) | 22 (7.4) | 0.16 |
|  | HSV ulcer for >1month | 4 (1.0) | 0 (0.0) | 4 (1.3) | 0.56 |
|  | KS | 2 (0.5) | 0 (0.0) | 2 (0.67) | 1.00 |
|  | Cachexia | 24 (5.9) | 5 (4.8) | 19 (6.4) | 0.64 |
| **Baseline CD4 count (cells/μl)f** | Median (IQR) | 152 (85-225) | 240 (140-351) | 133 (74-187) | <0.001 |
| **Baseline viral load (copies/ml)g** | Median (IQR) | 18000 (27–78000) | 25 (25-365) | 36000 (6800-100000) | <0.001 |
|  | <400 | 76 (27.3) | 51 (75.0) | 25 (11.9) | <0.001 |
| **Baseline WHO stage** | I | 75 (18.6) | 25 (23.8) | 50 (16.7) | 0.29 |
|  | II | 68 (16.8) | 20 (19.1) | 48 (16.1) |  |
|  | III | 216 (53.5) | 50 (47.6) | 166 (55.5) |  |
|  | IV | 45 (11.1) | 10 (9.5) | 35 (11.7) |  |
| **Starting regimensh** | D4T 3TC EFV | 379 (93.8) | 90 (85.7) | 289 (96.7) | <0.001h |
|  | D4T 3TC NVP | 9 (2.2) | 3 (2.9) | 6 (2.0) |  |
|  | AZT 3TC EFV | 10 (2.5) | 7 (6.7) | 3 (1.0) |  |
|  | AZT 3TC NVP | 2 (0.5) | 1 (1.0) | 1 (0.3) |  |
|  | AZT DDI KAL | 3 (0.7) | 3 (2.9) | 0 (0.0) |  |
|  | Unknown | 1 (0.3) | 1 (1.0) | 0 (0.0) |  |
| **Time to ART start (days)** | Median (IQR) | 23 (0-56) | 0 (0-7) | 32 (14-73) | <0.001 |

ART: antiretroviral therapy; IQR: interquartile range; TB: tuberculosis; WHO: World Health Organization; OHL: oral hairy leukoplakia; HSV: Herpes Simplex Virus; KS: Kaposi’s sarcoma

an(%) unless other indicated.

bdenominator=404 unless otherwise indicated.

cdenominator=105 unless otherwise indicated.

ddenominator=299 unless otherwise indicated.

eAccording to CDC 2008 criteria (<http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5710a2.htm>)

fdenominator=323 (85 ART-experienced and 238 ART-naïve).

gdenominator=278 (68 ART-experienced and 210-ART naïve).

hD4T=stavudine; 3TC=lamivudine; EFV=efavirenz; NVP=nevirapine; AZT=zidovudine; DDI=didanosine; KAL=kaletra (lopinavir/ritonavir); TDF=tenofovir;

hcomparing D4T, 3TC and EFV with all other regimens